Pharmaceutical
Learn about the latest developments in the pharmaceutical cannabis industry with Business of Cannabis. Discover new drugs, research, and more.
Pharmaceutical · page 2
- Medical Cannabis
Vertanical Secures Milestone FDA Breakthrough Designation for Cannabis Pain Drug Ahead of Imminent European Launch
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to VER-01, the flagship full-spectrum cannabis drug from Munich-based Vertanical, putting it in prime position to become the first FDA-approved cannabis-derived medicine for pain, and only the second such approval since Epidiolex in 2018.
- Pharmaceutical
German Distributor Fette Pharma Emerges From Restructuring Under New Investor Leadership
German medicinal cannabis distributor Fette Pharma GmbH has reported the successful completion of a strategic restructuring, almost seven months after an investor consortium led by entrepreneur Jörg Löser acquired the Egelsbach-based company in September 2025.
- Medical Cannabis
Cannabis Europa Paris 2026: France’s Medical Cannabis Reimbursement Plans Revealed
Today (February 19, 2026), Cannabis Europa returns to the French capital for the first time since 2019 at a critical juncture for the incoming French medical cannabis industry.
- Medical Cannabis
France’s Long-Awaited Medical Cannabis Reimbursement Framework to Be Revealed Next Week
French authorities will present a first draft of the long-awaited pricing and reimbursement decree for medical cannabis on February 18, marking a critical milestone in the country’s drawn-out transition from pilot programme to permanent framework.
- International Regulation
France’s Budget Chaos Nears Resolution, Removing Major Barrier for Medical Cannabis Rollout
Earlier this week (Tuesday, January 27), France’s government survived two no-confidence votes, finally passing its contentious 2026 budget following months of political crisis that had largely paralysed non-urgent policymaking.
- Medical Cannabis
Is Europe Moving Away From Cannabis Flower? – Why Companies Are Betting on CE-Certified Devices
Last week, we reported on an emerging trend in the European medical cannabis industry, which is seeing regulators in incoming markets favour alternative modes of administration, challenging the ubiquity of dried flower.
- International Regulation
Is Europe Moving Away From Cannabis Flower?
Spain’s medicines agency has published the first official guidance for medical cannabis preparations, confirming that its incoming market will exclude raw cannabis flower in favour of ‘standardised’ oral solutions prepared exclusively in hospital pharmacies.
- International Regulation
France’s First Prescriptions ‘Unlikely This Year’ Despite ‘Complete’ Framework
Last week, France’s now five-year old medical cannabis pilot programme was extended once again, providing a bridge beyond March 2026 for patients to continue secure access to their medication.
- Medical Cannabis
France Extends Medical Cannabis Access Again as Full Access Bill Remains Stuck in Limbo
Thousands of French medical cannabis patients will continue to receive their treatment for the foreseeable future, as the highly anticipated full generalised framework edges towards reality.
- Clinical Research
Cannabis Rescheduling is Here: Trump Signs Executive Order to Move Cannabis to Schedule III
After two years of speculation, rumours, stock swings, broken promises, and political theatre, President Donald Trump officially signed an executive order (EO) to push cannabis rescheduling through on Thursday (December 18).
- Clinical Research
‘Blockbuster’ Cannabis Drug To Be Released in 2026
Findings from the successful trials of a new, multi-compound, cannabis medicine look set to deliver a major breakthrough for the world’s half-a-billion chronic low back pain (CLB) sufferers.
- Clinical Research
Ananda Exits Landmark NHS-Funded Epilepsy Trial and Public Markets
Ananda Pharma, one of the UK’s leading clinical-stage pharmaceutical cannabis companies, has announced a string of strategic pivots, including stepping away from a flagship UK clinical trial into epilepsy.
